Wednesday, 15 August 2018 - 9:58
  • it
  • de
  • en
  • fr

AbbVie

AbbVie and Alphabet (Google) invest $1bn in cooperation

AbbVie and Alphabet announced today a three-year extension of their ongoing collaboration, aimed at developing new therapeutic solutions. Both companies are going to invest some $500m each in order to finance research work. Said work started in 2014, and has…

Trump’s fiscal reform will help AbbVie save billions

AbbVie, the manufacturer of the best-selling drug in the world–Humira–has surprised the financial community by announcing it expects a 9% tax rate in 2018, significantly lower than in 2017 , when it was 18.9%. This decrease is an effect of…

AbbVie invests in Ireland creating 100 jobs

AbbVie has announced a new €113m investment in its Sligo (Ireland) plant, which will create 100 new jobs. The investment is aimed at a sterile manufacturing expansion at the site, that will be used to produce cancer drugs. AbbVie CEO…

Biosimilar to Humira developed by Boehringer Ingelheim approved in Europe

The European Medicines Agency (EMA) has approved Boehringer Ingelheim’s Cyltezo, biosimilar to AbbVie’s blockbuster Humira. The Agency has recently approved the biosimilar to Humira developed by Amgen as well, which will be marketed as of October 2018 as Amgevita. The…

The evolution of blockbuster business according to JP Morgan

The research for new blockbusters has always been a priority for large pharma groups – a trend expected to continue. According to JP Morgan, an increasing number of drugs from the new category referred to as “personalized and precision medicine”…

Boehringer Ingelheim obtains FDA approval for biosimilar to Humira

Boehringer Ingelheim has obtained approval by the FDA for Cyltezo, the biosimilar to AbbVie’s immunosuppressant Humira. Cyltezo is the first biosimilar by the Germany-based group to be approved and is fairly significant as it provides an alternative to the best-selling…

Gilead to strengthen hepatitis C portfolio with Vosevi

Gilead strengthens its position in the hepatitis C treatment business by introducing a new product into its portfolio. The California-based group announced yesterday that FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablet) for the 12-week treatment of…

AbbVie’s pipeline

Humira, AbbVie’s blockbuster for the treatment of rheumatoid arthritis and other autoimmune disorders, generated over 16 billion dollars last year and analysts expect its sales volume to maintain this level over the next 4 years. Despite this, AbbVie invested a…

Biogen/AbbVie’s Zinbryta under review by PRAC

EMA PRAC (Pharmacovigilance Risk Assessment Committee) launched a review of Biogen/AbbVie’s Zinbryta (daclizumab). The product is intended to treat adult patients with relapsing forms of multiple sclerosis. The review follows the sudden death from liver failure of a patient who…

AbbVie loses fight against Coherus for patent of Humira

The US Patent and Trademark Office ruled in favor of Coherus Bioscience, in dispute with AbbVie over the patent covering Humira. The news caused AbbVie shares to drop by 4%, since Humira alone accounts for more than 60% of the…

A seemingly rosy future for biotech Enanta

The Wall Street Journal yesterday published a long article about US-based biotechnology company Enanta, which generates most of its revenue through the royalties paid by AbbVie for a key component of the hepatitis C drug Viekira Pak. However, the market…

2016 results from seven companies expected next week

BioPharmaDive has provided an interesting report of what we can expect from the pharma and biotech companies which will report their results next week. Such remarks are significant, especially following declarations by the US President-elect. As for Johnson & Johnson,…